Risk assessment of upper tract urothelial carcinoma related to aristolochic acid

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 5, 2013, Pages 812-820

  Wu, Felicia ^a   Wang, Tianxiu ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

ARISTOLOCHIA; ARTICLE; DISEASE ASSOCIATION; DNA ADDUCT; DOSE RESPONSE; ETHNICITY; FOOD INTAKE; GENE MUTATION; HERBAL MEDICINE; HUMAN; KIDNEY CORTEX; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; META ANALYSIS; ONCOGENE H RAS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; TRANSITIONAL CELL CARCINOMA;

ARISTOLOCHIC ACIDS; DRUGS, CHINESE HERBAL; HUMANS; KIDNEY FAILURE, CHRONIC; RISK ASSESSMENT; RISK FACTORS; URETHRAL NEOPLASMS;

EID: 84877978181     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1386     Document Type: Article

References (42)

1. Grollman AP, Scarborough J, Jelakovic B. Aristolochic acid nephropathy: An environmental and iatrogenic disease. Advances in molecular toxicology Vol. 3. Fischbein JC, editor. Oxford, UK: Elsevier; 2009.
2. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in youngwomen: Association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91.
3. Cosyns JP, Jadoul M, Squifflet JP, Van Cangh PJ, van Ypersele de Strihou C. Urothelial malignancy in nephropathy due to Chinese herbs. Lancet 1994;344:188.
4. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-92.
5. Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP. Upper urinary tract urothelial cancers: Where it is A:T. Nat Rev Cancer 2012;12: 503-4.
6. International Agency for Research on Cancer (IARC). Plants Containing Aristolochic Acid. In: A Review of Human Carcinogens: Pharmaceuticals, Volume 100A, 2012, http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-23.pdf.
7. Batuman V. Fifty years of Balkan endemic nephropathy: Daunting questions, elusive answers. Kidney Int 2006;69:644-6.
8. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of (Balkan) endemic nephropathy. Proc Natl Acad Sci U S A 2007;104:12129-34.
9. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, et al. Endemic nephropathy: The case for chronic poisoning by aristolochia. Croat Med J 2005;46:116-25.
10. Wild CP, Gong YY. Mycotoxins and human disease: A largely ignored global health issue. Carcinogenesis 2010;31:71-82.
11. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment. Environ Health Perspect 2010;118: 818-24.
12. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis. Eur J Cancer 2012;48:2125-36.
13. Moher D, Liberati A, Tetzlaff J, Altman DG: PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009;151:264-9.
14. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. 2nd ed. New York, NY: Springer-Verlag Inc; 2003.
15. Hartung J, Knapp G, Sinha BK. Statistical meta-analysis with applications. 1st ed Hoboken, NJ: John Wiley & Sons, Inc; 2008.
16. Ngo AD, Taylor R, Roberts CL, Nguyen TV. Association between Agent Orange and birth defects: Systematic review and meta-analysis. Int J Epidemiol 2006;35:1220-30.
17. IARC (International Agency for Research on Cancer). Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. Lyon, France: IARC Monogr Eval Carcinog Risks Hum 2002;82:69-128. Available from: Http://monographs.iarc.fr/ENG/Monographs/vol82/mono82-6B.pdf [accessed November 2011].
18. NTP (National Toxicology Program). Report on carcinogens background document for aristolochic acids. NTP 2008. Available from: Http://ntp.niehs.nih. gov/files/aristolochic-acid-public-version.pdf [accessed February 2012].
19. Wu MJ, Lian JD, Yang CR, Cheng CH, Chen CH, Lee WC, et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004;43:1091-7.
20. Li WH, Yang L, Su T, Song Y, Li XM. [Influence of taking aristolochic acid-containing Chinese drugs on occurrence of urinary transitional cell cancer in uremic patients undergoing dialysis.] Zhonghua Yi Xue Za Zhi 2005;85:2487-91.
21. Chang CH, Yang CM, Yang AH. Renal diagnosis of chronic hemodialysis patients With urinary tract transitional cell carcinoma in Taiwan. Cancer 2007;109:1487-92.
22. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD. Transitional cell carcinoma in renal transplant recipients: A single center experience. Int J Urol 2008;15:53-7.
23. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2009;102:179-86.
24. Xiao J, Zhu X, Hao GY, Zhu YC, Hou HJ, Zhang J, et al. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: The potential role of aristolochic acid in HRas and TP53 gene mutations. Transplant Proc 2011;43:3751-4.
25. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial carcinoma in Taiwan. Proc Natl Acad Sci U S A 2012;109:8241-6.
26. Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81:559-67.
27. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, et al. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 2012;21;25:1119-31.
28. Muniz Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: Impact of Aristolochia fangchi ingested dose. Nephrol Dial Transplant 2002;17:408-12.
29. Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: A population-based case-control study. Am J Kidney Dis 2010;55:507-18.
30. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: A worldwide problem. Kidney Int 2008;74:158-69.
31. Therapeutic Goods Administration (TGA). Aristolochia Fact Sheet-25 May 2001. TGA. 2001. Available from: Http://www.tga.gov.au/safety/alerts-medicine- aristolochia-010524.htm. [accessed February 2012].
32. UK Committee on Safety of Medicines (MHRA). The Medicines (Aristolochia and Mu Tong etc.) (Prohibition) Order 2001 (Statutory Instrument 2001 No. 1841). London. The Stationary Office. 2001. Available from: Http://www.legislation. gov.uk/uksi/2001/1841/contents/made. [accessed February 2012].
33. European Agency for the Evaluation of Medicinal Products (EMEA). Working Party on Herbal Medicinal Products: Position paper on the risks associated with the use of herbal products containing Aristolochia species (EMEA/HMPWP/23/00). London. EMEA 2000.
34. Available from: Http://www.emea.europa.eu/docs/en-GB/document-library/ Position-statement/2009/11/WC500015537.pdf. [accessed February 2012].
35. Grollman AP, Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. J Am Soc Nephrol 2007;18:2817-23.
36. Huang CY, Tseng MC, Lin JH. Analyzing aristolochic acids in Chinese herbal preparations using LC/MS/MS. J Food Drug Anal 2005;13: 125-31.
37. Chan W, Hui KM, Poon WT, Lee KC, Cai Z. Differentiation of herbs linked to "Chinese herb nephropathy" from the liquid chromatographic determination of aristolochic acids. Anal Chim Acta 2006;576:112-6.
38. Kvasnicka F, Sevcik R, Voldrich M, Kratka J. Determination of aristolochic acid by capillary zone electrophoresis. Cent Eur J Chem 2004;2:417-24.
39. Hsieh SC, Huang MF, Lin BS, Chang HT. Determination of aristolochic acid in Chinese herbal medicine by capillary electrophoresis with laserinduced fluorescence detection. J Chromatogr A 2006;1105:127-34.
40. Rao M,Mottl AK, Cole SA, Umans JG, Freedman BI, Bowden DW, et al. Meta-analysis of genome-wide linkage scans for renal function traits. Nephrol Dial Transplant 2012;27:647-56.
41. Roupret M, Drouin SJ, Cancel-Tassin G, Comperat E, Larre S, Cussenot O. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol 2012;187:424-8.
42. Yates DR, Roupret M, Drouin SJ, Audouin M, Cancel-Tassin G, Comperat E, et al. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. World J Urol 2013;31:53-9.